Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus
(HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving
different doses of DEB025 in combination with ribavirin (RBV) during the first 12 weeks
treatment in chronic hepatitis C genotype (GT)-2 and GT-3 patients who had previously failed
interferon therapy or were intolerant or unable to take interferon.